CD8A and neoplasm: The delivery of Lm-LLO-ISG15 i.p. was associated with significant anti-tumor therapeutic efficacy, although the ability to generate an antigen-specific CD8+ T cell-mediated anti-tumor response between i.p. versus p.o was comparable.